[go: up one dir, main page]

EA200600987A1 - APPLICATION OF SYRAMEZIN IN THE TREATMENT OF MALIGNANT TUMORS - Google Patents

APPLICATION OF SYRAMEZIN IN THE TREATMENT OF MALIGNANT TUMORS

Info

Publication number
EA200600987A1
EA200600987A1 EA200600987A EA200600987A EA200600987A1 EA 200600987 A1 EA200600987 A1 EA 200600987A1 EA 200600987 A EA200600987 A EA 200600987A EA 200600987 A EA200600987 A EA 200600987A EA 200600987 A1 EA200600987 A1 EA 200600987A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
malignant tumors
syramezin
application
relates
Prior art date
Application number
EA200600987A
Other languages
Russian (ru)
Other versions
EA011170B1 (en
Inventor
Христиан Томсен
Марсель Ляйст
Марья Яттела
Мария Стампе Андерсен
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200600987A1 publication Critical patent/EA200600987A1/en
Publication of EA011170B1 publication Critical patent/EA011170B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к лечению злокачественных опухолей. В частности, изобретение относится к фармацевтическим композициям, содержащим сирамезин и предназначенным для лечения злокачественных опухолей. Изобретение также относится к способу лечения, включающему введение сирамезина пациенту, страдающему от злокачественной опухоли.The present invention relates to the treatment of malignant tumors. In particular, the invention relates to pharmaceutical compositions containing siramesin and intended for the treatment of malignant tumors. The invention also relates to a method of treatment comprising administering siramezin to a patient suffering from a malignant tumor.

EA200600987A 2003-12-19 2004-12-17 Use of siramesine in the treatment of cancer EA011170B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53167003P 2003-12-19 2003-12-19
DKPA200301889 2003-12-19
PCT/DK2004/000885 WO2005058324A1 (en) 2003-12-19 2004-12-17 Use of siramesine in the treatment of cancer

Publications (2)

Publication Number Publication Date
EA200600987A1 true EA200600987A1 (en) 2006-10-27
EA011170B1 EA011170B1 (en) 2009-02-27

Family

ID=34702153

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600987A EA011170B1 (en) 2003-12-19 2004-12-17 Use of siramesine in the treatment of cancer

Country Status (8)

Country Link
EP (1) EP1715864A1 (en)
JP (1) JP2007514666A (en)
AU (1) AU2004298722A1 (en)
BR (1) BRPI0416019A (en)
CA (1) CA2550611A1 (en)
EA (1) EA011170B1 (en)
NO (1) NO20063319L (en)
WO (1) WO2005058324A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013789A1 (en) * 2000-08-15 2002-02-21 H. Lundbeck A/S Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression

Also Published As

Publication number Publication date
EA011170B1 (en) 2009-02-27
AU2004298722A1 (en) 2005-06-30
WO2005058324A1 (en) 2005-06-30
BRPI0416019A (en) 2007-01-02
JP2007514666A (en) 2007-06-07
EP1715864A1 (en) 2006-11-02
CA2550611A1 (en) 2005-06-30
NO20063319L (en) 2006-07-18

Similar Documents

Publication Publication Date Title
ATE442142T1 (en) FREDERICAMYCIN DERIVATIVES AS DRUGS FOR TUMOR TREATMENT
MY151032A (en) Treatment of tnf? related disorders
ATE330967T1 (en) PEPTIDE COMPOUNDS BINDING TO HER2
EA200501849A1 (en) DERIVATIVES OF PYRAZOLOHINAZOLINE: METHOD FOR OBTAINING AND USING AS KINAZ INHIBITORS
EA200601212A1 (en) PHOSPHODESTERASE INHIBITORS, OBTAINING AND THEIR THERAPEUTIC APPLICATION
NO20071426L (en) Cancer combination therapy including AZD2171 and Imatinib
MX2007011545A (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors.
BR0306715A (en) Methods for diagnosis and treatment of tumors
DE60021381D1 (en) CHINONIC COMPOUNDS FOR THE TREATMENT OF DISEASES
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
EA200500244A1 (en) TETRAPROPILAMMONIA TETRATIOMOLYBDAT AND RELATED COMPOUNDS FOR ANTIANGIOGENIC THERAPY
MX2007002269A (en) Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain.
IS6558A (en) Mixed disease treatment with vasoconstrictor
EA200501821A1 (en) PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
DE60311788D1 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
TW200504051A (en) Novel acridine derivatives and their use as medicaments
EA200600987A1 (en) APPLICATION OF SYRAMEZIN IN THE TREATMENT OF MALIGNANT TUMORS
MXPA05013975A (en) Treatment of amyloid- and epileptogenesis-associated diseases.
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
ATE412411T1 (en) PMCOL FOR THE TREATMENT OF PROSTATE CANCER
DE60334289D1 (en) DITHIOLOPYRROLONE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDER
ATE423780T1 (en) MACROCYCLES FOR THE TREATMENT OF CANCER DISEASES
IL191690A0 (en) Therapy of malignant neoplasias
DE502005010237D1 (en) STABLE DOSAGE FOR PHENYLALANINE DERIVATIVES

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU